Fig. 3From: A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trialKaplan–Meier estimates of progression-free survival from the start of first treatment to first documented disease progression or death, whichever occurred earlier, among patients who received pomalidomide plus low-dose dexamethasone in MM-011Back to article page